Session » Immunological Complications of Therapy Poster (1516–1529)
-
Abstract Number: 1516
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
-
Abstract Number: 1517
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
-
Abstract Number: 1518
Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
-
Abstract Number: 1519
Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers
-
Abstract Number: 1520
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
-
Abstract Number: 1521
Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
-
Abstract Number: 1522
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
-
Abstract Number: 1523
Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution
-
Abstract Number: 1524
COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population
-
Abstract Number: 1525
Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
-
Abstract Number: 1526
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
-
Abstract Number: 1527
Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
-
Abstract Number: 1528
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
-
Abstract Number: 1529
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy